Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome

Rifaximin, a non-systemic antibiotic, is efficacious for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). Given the emerging association between the gut microbiota and IBS, this study examined potential effects of rifaximin on the gastrointestinal microbial community in patie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Gut Microbes
Egile Nagusiak: Fodor, Anthony A., Pimentel, Mark, Chey, William D., Lembo, Anthony, Golden, Pamela L., Israel, Robert J., Carroll, Ian M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2018
Gaiak:
Research Paper/Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363070/
https://ncbi.nlm.nih.gov/pubmed/29708822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19490976.2018.1460013
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak